PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542920
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542920
Global Sepsis Diagnostic Market - 2024-2031
Report Overview
The Global Sepsis Diagnostics Market reached US$ 710.13 million in 2023 and is expected to reach US$ 1,435.24 million by 2031, growing at a CAGR of 9.5% during the forecast period 2024-2031.
Sepsis is a life-threatening illness that occurs when the body's immune system overreacts to an infection, causing organ malfunction. The body's response damages its tissues and organs, which can result in shock, multiple organ failure, and even death if not detected and treated swiftly.
Blood tests and other lab tests such as urine, liquid from the wound, mucus, and saliva from the respiratory tract are performed to diagnose the condition.
Market Dynamics: Drivers & Restraints
The growing burden of infectious diseases
If infectious infections are not detected and treated promptly, they can develop into serious conditions such as sepsis. As a result, there is a greater emphasis on early diagnosis of infections that could develop into sepsis. Diagnostic tests for sepsis assist healthcare providers in detecting the condition early, allowing for appropriate intervention and management. HAIs are hospital-acquired infections that can significantly contribute to sepsis cases.
As healthcare-associated infections continue to rise, there is a greater need for precise diagnostic tools to monitor patients and diagnose sepsis early in these settings.
In Europe, the burden of the six most frequent HAIs was calculated to be twice the burden of 32 other infectious diseases altogether, in terms of disability and premature mortality.
Additionally, according to research published by 2023 Balasubramanian et al., an estimated 136 million cases of healthcare-associated antibiotic-resistant infections occur worldwide every year. Thus, the increasing burden of infectious diseases is expected to drive the market growth.
High Cost of Diagnostic Tools
Automated diagnostic instruments and biomarker tests can be costly. High upfront expenses could result in a slower overall adoption rate among medical facilities. This directly translates into slower growth in the sepsis diagnostics market. Despite these limitations, hospitals will continue to use older, less expensive methods.
Segment Analysis
The global sepsis diagnostic market is segmented based on product, technology, diagnostic method, pathogen, end-user and region.
Blood Culture Media segment is expected to dominate the market growth
Blood culture media is expected to be the dominant segment in the sepsis diagnostics market. Blood culture media is a less expensive diagnostic technique than other approaches such as molecular diagnostics. Blood culture media is readily accessible and simple in most therapeutic settings.
While more rapid approaches are emerging, blood cultures remain the accepted standard for identifying the specific pathogens causing sepsis since they allow for the growth and identification of bacteria or fungi. Thus, the above factors are expected to hold the segment in the dominant position.
Geographical Analysis
North America is expected to hold a significant position in the sepsis diagnostic market share
North America is expected to dominate the sepsis diagnostic market owing to the increasing prevalence of sepsis and the technological advancements in sepsis diagnosis such as advanced diagnostic facilities and high adoption rates of medical technologies are expected to drive the market growth in the region. The medical diagnostic companies in the region are introducing several tests and the required sepsis diagnostic tools which could help in driving the market growth.
Foe instance, in August 2023, Medical diagnostic company Cytovale commercially introduced its new diagnostic tool, the IntelliSep sepsis test, in the US. The test was launched following 510(k) clearance from the US Food and Drug Administration in December 2022.
Additionally, on April 3, 2024, Prenosis, Inc. received the U.S. Food and Drug Administration (FDA) approval of the marketing authorization for the Sepsis ImmunoScoreTM using the De Novo pathway. The Sepsis ImmunoScoreTM is an artificial intelligence/machine learning software as a medical device (AI SaMD) to guide rapid diagnosis and prediction of sepsis. Thus, the above factors are expected to hold the region in the dominant position.
Market Segmentation
By Product
Instruments
Software
Blood Culture Media
Assays & Reagents
Others
By Technology
Flow Cytometry
Microbiology
Biomarkers
Molecular Diagnostics
Microfluidics
Others
By Pathogen
Automated Diagnostics
Conventional Diagnostics
By Diagnostic Method
Fungal Sepsis
Bacterial Sepsis
Gram-Positive Bacterial Sepsis
Gram-Negative Bacterial Sepsis
Other Pathogens
By End-User
Hospitals
Pathology & Reference Laboratories
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
Middle East and Africa
Competitive Landscape
The major global players in the market include Thermo Fisher Scientific Inc., Bruker Corporation, Merck Millipore, Siemens Healthineers, Becton, Dickinson, and Company, Hoffmann-LA Roche Ltd, T2 Biosystems, Inc., Response Biomedical Corp., BioMerieux SA, and Immunexpress Inc. among others.
Key Developments
On April 18, 2023, Carle Illinois College of Medicine faculty member Rashid Bashir received marketing approval from the Food and Drug Administration for A new AI tool for sepsis diagnosis developed from research.
On November 27, 2023, Asep Medical Holdings Inc. secured patent approval in the US for its AI-based sepsis diagnostic technology, SepsetER.
Why Purchase the Report?
To visualize the global Sepsis Diagnostic market segmentation based on Product, Technology, Diagnostic Method, Pathogen and End-User and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of Sepsis Diagnostic market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global Sepsis Diagnostic market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Product
- 3.2. Snippet by Technology
- 3.3. Snippet by Diagnostic Method
- 3.4. Snippet by Technology
- 3.5. Snippet by End-User
- 3.6. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Growing burden of infectious diseases
- 4.1.2. Restraints
- 4.1.2.1. High cost of diagnostic tools
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
6. By Product
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 6.1.2. Market Attractiveness Index, By Product
- 6.2. Instruments *
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Software
- 6.4. Blood Culture Media
- 6.5. Assays & Reagents
- 6.6. Others
7. By Technology
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 7.1.2. Market Attractiveness Index, By Technology
- 7.2. Flow Cytometry*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Microbiology
- 7.4. Biomarkers
- 7.5. Molecular Diagnostics
- 7.6. Microfluidics
- 7.7. Others
8. By Diagnostic Method
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
- 8.1.2. Market Attractiveness Index, By Diagnostic Method
- 8.2. Automated Diagnostics*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Conventional Diagnostics
9. By Pathogen
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
- 9.1.2. Market Attractiveness Index, By Pathogen
- 9.2. Fungal Sepsis*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Bacterial Sepsis
- 9.3.1. Gram-Positive Bacterial Sepsis
- 9.3.2. Gram-Negative Bacterial Sepsis
- 9.4. Other Pathogens
10. By End-User
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
- 10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Pathology & Reference Laboratories
- 10.4. Others
11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
- 11.2.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
- 11.2.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.4.1. U.S.
- 11.2.4.2. Canada
- 11.2.4.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
- 11.3.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.5.1. Germany
- 11.3.5.2. UK
- 11.3.5.3. France
- 11.3.5.4. Italy
- 11.3.5.5. Spain
- 11.3.5.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
- 11.4.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.5.1. Brazil
- 11.4.5.2. Argentina
- 11.4.5.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
- 11.5.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.5.1. China
- 11.5.5.2. India
- 11.5.5.3. Japan
- 11.5.5.4. Australia
- 11.5.5.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 11.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Method
- 11.6.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
- 11.6.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
13. Company Profiles
- 13.1. Thermo Fisher Scientific Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Bruker Corporation
- 13.3. Merck Millipore
- 13.4. Siemens Healthineers
- 13.5. Becton, Dickinson, and Company
- 13.6. Hoffmann-LA Roche Ltd
- 13.7. T2 Biosystems, Inc.
- 13.8. Response Biomedical Corp.
- 13.9. BioMerieux SA
- 13.10. Immunexpress Inc. (LIST NOT EXHAUSTIVE)
14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
